WO2011136634A1 - Prévention de la perte de poids due à une infection à salmonella - Google Patents

Prévention de la perte de poids due à une infection à salmonella Download PDF

Info

Publication number
WO2011136634A1
WO2011136634A1 PCT/NL2010/050226 NL2010050226W WO2011136634A1 WO 2011136634 A1 WO2011136634 A1 WO 2011136634A1 NL 2010050226 W NL2010050226 W NL 2010050226W WO 2011136634 A1 WO2011136634 A1 WO 2011136634A1
Authority
WO
WIPO (PCT)
Prior art keywords
infection
pdp
use according
composition
salmonella infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2010/050226
Other languages
English (en)
Inventor
Richèle Deodata Wind
Cornelus Johannes Petrus Van Limpt
Bernd Stahl
Sander Hougee
Jan Knol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to PCT/NL2010/050226 priority Critical patent/WO2011136634A1/fr
Publication of WO2011136634A1 publication Critical patent/WO2011136634A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a nutritional composition and its use in infection-induced weight loss control, particularly in case of (increased risk of) salmonella infections.
  • the present inventors found that weight loss in subjects suffering from infection, particularly subjects infected with salmonella, or at risk of such infection, can be limited and/or weight gain can be improved by orally ingesting pectin degradation product (PDP) before, during and/or after the infection.
  • PDP pectin degradation product
  • the PDP can be included in foods products which are consumed by the fragile subjects in order to remain well-nourished.
  • infants receive infant formula and hospitalized patients can receive liquid enteral nutrition.
  • the PDP can be included in such products.
  • weight loss can be reduced or prevented, if a subject receiving the food product with PDP becomes infected with salmonella.
  • a composition comprising PDP can be administered after the subject has been diagnosed with salmonella infection or salmonellosis.
  • the present invention thus concerns a method for prevention and/or treatment of weight reduction in subjects suffering from salmonella infection or susceptible to salmonella infection, said method comprising adminstering a composition comprising pectin degradation product (PDP).
  • PDP pectin degradation product
  • the invention concerns the use of pectin degradation product (PDP) in the manufacture of a composition for prevention and/or treatment of weight reduction in subjects suffering from salmonella infection or susceptible to salmonella infection.
  • PDP pectin degradation product
  • the invention can also be worded as a composition comprising pectin degradation product (PDP) for use in the prevention and/or treatment of weight reduction in subjects suffering from salmonella infection or susceptible to salmonella infection.
  • PDP pectin degradation product
  • the term 'elderly' as used in the present invention means people aged 55 years and older, more preferably of age 60 years and older.
  • the term 'infants' represents children aged 5 years or younger, more preferably of age 3 years or less, preferably of 0 - 36 months.
  • the treatment and/or prevention is for a subject that has an age of 55 years or more.
  • the treatment and/or prevention is for a subject that has an age of 3 years or less.
  • pectin degradation product is merely intended to distinguish such pectin-derived preparations as are commercially available from the (nutritional) compositions incorporating such PDP.
  • pectin degradation product is considered interchangeable by “pectin degradation preparation”.
  • pectin degradation product it is preferably understood a pectin hydrolysate (prepared by hydrolysis) and/or pectin lyasate (prepared by beta- elimination).
  • the pectin degradation product is preferably prepared from fruit and/or vegetable pectin, more preferably apple pectin, citrus pectin and/or sugar beet pectin.
  • the pectin degradation product is preferably prepared with lyases and/or variations of the temperature and pressure, more preferably by beta-elimination.
  • the pectin degradation product is preferably a pectin lyasate.
  • the pectin degradation product preferably has a DP between 2 and 250, more preferably between 2 and 100, and this DP is preferably an average DP.
  • the present composition comprises uronic acid oligosaccharide.
  • the Oligosaccharides preferably have a DP of 2 to 100, even more preferably a DP of 2 to 50, most preferably a DP of 2 to 20.
  • the pectin degradation product comprises between 25 and 100 wt%, more preferably between 50 and 100 wt% of said uronic acid oligosaccharides, based on total weight of uronic acid in the product.
  • the uronic acid oligosaccharides are preferably obtainable or obtained by enzymatic digestion of pectin with pectin lyases, pectate lyase, endopolygalacturonase and/or pectinase.
  • the uronic acid oligosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified.
  • the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and altruronic acid. These units may be free or esterified.
  • at least one of the terminal hexuronic acid units of the uronic acid oligosaccharide has a double bond, which is preferably situated between the C4 and C5 position of the terminal hexuronic acid unit.
  • one of the terminal hexuronic acid units comprises the double bond.
  • the double bond at terminal hexuronic acid unit can for example be obtained by enzymatic hydrolysis of pectin with lyase.
  • the carboxylic acid groups on these uronic acid units may be free or (partly) esterified, and are preferably at least partly methylated.
  • the uronic acid oligosaccharides are preferably galacturonic acid oligosaccharides.
  • the present composition contains between 25 and 100 wt%, preferably between 50 and 100 wt% galacturonic acid oligosaccharide with a degree of polymerization (DP) of 2 to 250, more preferably DP 2 - 100, most preferably DP 2 - 50, based on total weight of galacturonic acid in the composition. Most preferably, the degree of polymerisation is an average DP.
  • DP degree of polymerization
  • the present composition is preferably administered enterally, more preferably orally.
  • the present composition is preferably a nutritional formula.
  • the present composition preferably comprises lipid, protein, and carbohydrate and is preferably administered in liquid form.
  • the present invention includes dry compositions, e.g. powders, which are accompanied with instructions as to admix said dry compositions, in particular nutritional formula, with a suitable liquid, e.g. water.
  • the present (nutritional) composition preferably contains between 0.01 and 5 grams of said PDP, more preferably 0.01- 5 grams galacturonic acid oligosaccharide; more preferably between 0.05 and 2 grams per 100 grams dry weight.
  • the present method preferably comprises the administration of between 0.05 and 10 grams PDP per day, even more preferably between 0.1 and 5 grams PDP per day. Hence in the use according to the invention, preferably between 0.05 and 10 grams PDP is administered per day.
  • the present composition When formulated as a nutritional composition, the present composition preferably contains 5 to 16 en% protein; 35 to 60 en% fat; and 25 to 75 en% carbohydrates, preferably 5 to 12.0 en% protein; 39 to 50 en% fat; and 40 to 55 en% carbohydrates (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
  • en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation.
  • en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation.
  • the composition is preferably an enteral composition suited for elderly and/or hospitalized patients. These subjects are often troubled by reduced appetite or disturbed eating behaviour. For that purpose, it is strived for a composition that is desirably liquid with a sufficiently low viscosity so it can be easily swallowed.
  • the viscosity of the liquid enteral nutritional composition is lower than 500 mPa.s, measured at 20 °C (i.e. room temperature) at a shear rate of 100 s "1 , preferably between 10 and 200 mPa.s, more preferably between 10 and 100 mPa.s.
  • the viscosity may suitably be determined using a rotational viscosity meter using a cone/plate geometry.
  • the present composition preferably comprises at least one lipid selected from the group consisting of animal lipid (excluding human lipids) and vegetable lipids.
  • the present composition comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, animal oil, algae oil, fungal oil, and bacterial oil.
  • the protein component used in the nutritional preparation are preferably selected from the group consisting of non-human animal proteins (preferably milk proteins, preferably proteins from cow's milk), vegetable proteins (preferably soy protein and/or rice protein), free amino acids and mixtures thereof.
  • the present composition preferably contains casein, whey, hydro lysed casein and/or hydro lysed whey protein.
  • the protein comprises intact proteins, more preferably intact bovine whey proteins and/or intact bovine casein proteins.
  • the protein is preferably selected from the group consisting of hydro lyzed milk protein.
  • the liquid nutritional composition preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml.
  • the present invention provides a composition as described herein above accompanied with indications (e.g. written material) comprising statement that the administration of the composition prevents or reduces weight loss, or improves weight gain.
  • indications e.g. written material
  • the invention pertains to the use of said PDP in the manufacture of a composition for the prevention/treatment of infection-induced weight loss, preferably salmonella infection-induced weight loss.
  • the invention pertains to the above-described nutritional composition comprising PDP for use in the prevention and/or treatment of infection- induced weight loss, preferably salmonella infection-induced weight loss.
  • the invention pertains to a method for preventing and/or treatment infection-induced weight loss, preferably salmonella infection-induced weight loss, in a subject suffering from said infection, or a subject being at risk of said infection, wherein said method involves administering to said subject a nutritional composition comprising PDP as described above.
  • a subject suffering from salmonella infection includes subjects diagnosed with gastroenteritis, typhoid fever, paratyphoid fever.
  • the present invention aims to prevent body weight reduction, and perferably aims to increase body weight, preferably in subjects infected with salmonella, and subjects susceptible to salmonella infection, particularly infants and elderly.
  • the subjects susceptible to (i.e. at risk of) salmonella infection include infants, elderly, hospitalized patients, subjects with an impaired health status, particularly malnourished subjects.
  • the invention is for prevention of weight loss. In one embodiment the invention is for reducing the risk of weight loss. In one embodiment the invention is for treatment of weight loss.
  • the salmonella infection is infection by Salmonella enteritidis.
  • the PDP may be co-administered with antibiotics aiming to treat the infection.
  • mice Two concentrations of pectin-derived acidic oligosaccharides (1% and 5% w/w) were tested in a Salmonella enteritidis infection model in young male BALB/c mice. Mice (26 per group) were supplemented via the chow with these acidic oligosaccharides during the entire experiment (34 days). After 28 days the mice (20 per group) were challenged with 10 5 cfu of a virulent Salmonella enteritidis strain by oral gavage and subsequently sacrificed six days after infection. An infection control group was also included in this study as positive control, receiving standard rodent show (AIN-93G). Weight development was monitored during the entire experiment. After sacrificing the animals, gross weight was measured.
  • Salmonella enteritidis infected mice fed with acidic oligosaccharides showed improved health related behavior in a dose dependent manner. Infection related weight loss was significantly ameliorated in the AOS supplemented mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé impliquant d'administrer un produit issu de la dégradation de la pectine dans le but de prévenir et/ou de traiter une perte de poids chez des sujets souffrant d'une infection à salmonella ou risquant une infection à salmonella.
PCT/NL2010/050226 2010-04-26 2010-04-26 Prévention de la perte de poids due à une infection à salmonella Ceased WO2011136634A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/NL2010/050226 WO2011136634A1 (fr) 2010-04-26 2010-04-26 Prévention de la perte de poids due à une infection à salmonella

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2010/050226 WO2011136634A1 (fr) 2010-04-26 2010-04-26 Prévention de la perte de poids due à une infection à salmonella

Publications (1)

Publication Number Publication Date
WO2011136634A1 true WO2011136634A1 (fr) 2011-11-03

Family

ID=42676859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050226 Ceased WO2011136634A1 (fr) 2010-04-26 2010-04-26 Prévention de la perte de poids due à une infection à salmonella

Country Status (1)

Country Link
WO (1) WO2011136634A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019112418A1 (fr) 2017-12-04 2019-06-13 Nutrileads B.V. Composition destinée à être utilisée dans la prévention ou le traitement de la salmonellose
CN112739417A (zh) * 2018-09-07 2021-04-30 纽崔利兹有限公司 用于治疗与肠道微生物组的扰乱的组成或功能有关的病症的益生元
US11723915B2 (en) 2017-10-23 2023-08-15 Nutrileads B.V. Enzymatically hydrolysed pectic polysaccharides for treating or preventing infections
US12415871B2 (en) 2017-10-23 2025-09-16 Nutrileads B.V. Method of producing a pectic polysaccharide isolate enriched in rhamnogalacturonan-I

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067000A1 (fr) * 2007-11-20 2009-05-28 N.V. Nutricia Composition contenant des symbiotiques
WO2009075564A1 (fr) * 2007-12-10 2009-06-18 N.V. Nutricia Mélange de fibres pédiatriques
EP2130440A1 (fr) * 2008-06-06 2009-12-09 N.V. Nutricia Inhibition de croissance E. Sakazakii

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067000A1 (fr) * 2007-11-20 2009-05-28 N.V. Nutricia Composition contenant des symbiotiques
WO2009075564A1 (fr) * 2007-12-10 2009-06-18 N.V. Nutricia Mélange de fibres pédiatriques
EP2130440A1 (fr) * 2008-06-06 2009-12-09 N.V. Nutricia Inhibition de croissance E. Sakazakii

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723915B2 (en) 2017-10-23 2023-08-15 Nutrileads B.V. Enzymatically hydrolysed pectic polysaccharides for treating or preventing infections
US12415871B2 (en) 2017-10-23 2025-09-16 Nutrileads B.V. Method of producing a pectic polysaccharide isolate enriched in rhamnogalacturonan-I
WO2019112418A1 (fr) 2017-12-04 2019-06-13 Nutrileads B.V. Composition destinée à être utilisée dans la prévention ou le traitement de la salmonellose
CN111447935A (zh) * 2017-12-04 2020-07-24 纽崔利兹有限公司 用于预防或治疗沙门氏菌病的组合物
JP2021514383A (ja) * 2017-12-04 2021-06-10 ニュートリリーズ ビー．ヴイ．Ｎｕｔｒｉｌｅａｄｓ Ｂ．Ｖ． サルモネラ症の予防又は治療に使用するための組成物
US11524025B2 (en) 2017-12-04 2022-12-13 Nutrileads B.V. Composition for use in the prevention or treatment of salmonellosis
CN112739417A (zh) * 2018-09-07 2021-04-30 纽崔利兹有限公司 用于治疗与肠道微生物组的扰乱的组成或功能有关的病症的益生元
CN112739417B (zh) * 2018-09-07 2025-07-01 纽崔利兹有限公司 用于调节肠道微生物群的益生元

Similar Documents

Publication Publication Date Title
RU2426549C2 (ru) Детское питание, стимулирующее иммунитет
ES2781848T3 (es) Oligosacáridos inmunomoduladores
US9883692B2 (en) Nutrition with non-viable bifidobacterium and nondigestible oligosaccharide
RU2402929C2 (ru) Применение смеси транс-галакто-олигосахаридов и инулина
DK1571923T3 (en) PREBIOTIC COMPOSITIONS
EP2525811B1 (fr) Une composition comprenant du lactobacillus rhamnosus hn001 et des prébiotiques pour le traitement des maladies pulmonaires allergiques
US11559554B2 (en) Multifiber prebiotic composition for digestive health, weight control, boosting immunity and improving health
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
WO2011136634A1 (fr) Prévention de la perte de poids due à une infection à salmonella
EP1957084B1 (fr) Préparation contenant des oligosaccharides pour le traitement prophylactique/thérapeutique de la fiebre et des crises hyperpyrétiques
Sharma et al. Miraculous health benefits of prebiotics
AU2018431641B2 (en) Nutritional composition for use in the treatment of diarrhea, its preparation and method of treatment
CN1871015B (zh) 免疫调节性寡糖
MXPA06004523A (en) Immunemodulating oligosaccharides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10718313

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10718313

Country of ref document: EP

Kind code of ref document: A1